Ipragliflozin-<wbr/><sup>13</sup>C<sub>6</sub></wbr>

Ipragliflozin-13C6

CAT N°: 28705
Price:

359.00 305.15

Ipragliflozin-13C6 is intended for use as an internal standard for the quantification of ipragliflozin (Item No. 22287) by GC- or LC-MS. Ipragliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor (IC50 = 7.4 nM in CHO cells expressing the human cotransporter).{49504} It is selective for SGLT2 over SGLT1, SGLT3, SGLT4, SGLT5, and SGLT6 (IC50s = 1.9, 30.4, 15.9, 0.46, and 10.4 µM, respectively). Ipragliflozin (0.1-3 mg/kg) decreases plasma levels of insulin and glucose in an oral glucose tolerance test in a mouse model of diabetes induced by high-fat diet, streptozotocin (STZ; Item No. 13104), and nicotinamide (Item No. 11127).{49505} It decreases plasma and hepatic IL-6, TNF-?, chemokine (C-C motif) ligand 2 (CCL2), and C-reactive protein (CRP) levels in the same model when administered at a dose of 3 mg/kg per day for 28 days.

We also advise you